| 000 | 01802 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518082708.0 | ||
| 264 | 0 | _c20201023 | |
| 008 | 202010s 0 0 eng d | ||
| 022 | _a2162-0989 | ||
| 024 | 7 |
_a10.1097/01.APO.0000617924.11529.88 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSpooner, Kimberly | |
| 245 | 0 | 0 |
_aEffects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion. _h[electronic resource] |
| 260 |
_bAsia-Pacific journal of ophthalmology (Philadelphia, Pa.) _c |
||
| 300 |
_a48-53 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aBevacizumab _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aDrug Substitution |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 |
_aMacular Edema _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRanibizumab _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptors, Vascular Endothelial Growth Factor _xtherapeutic use |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xtherapeutic use |
| 650 | 0 | 4 |
_aRetinal Vein Occlusion _xcomplications |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aTomography, Optical Coherence |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVisual Acuity _xphysiology |
| 700 | 1 | _aFraser-Bell, Samantha | |
| 700 | 1 | _aHong, Thomas | |
| 700 | 1 | _aChang, Andrew | |
| 773 | 0 |
_tAsia-Pacific journal of ophthalmology (Philadelphia, Pa.) _gvol. 9 _gno. 1 _gp. 48-53 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/01.APO.0000617924.11529.88 _zAvailable from publisher's website |
| 999 |
_c30569178 _d30569178 |
||